NCT07014215View on ClinicalTrials.gov

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2029

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)Resistance to Immunotherapy
Interventions
DRUG

Sintilimab combined with Bevacizumab and tafolecimab

Patients who met the inclusion criteria were treated with sintilimab(200mg Q3W) combined with Bevacizumab(7.5mg/kg Q3W) and tafolecimab(600mg Q6W) until disease progression or intolerable adverse reactions or death(up to 24 months)

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER